Vyant Bio, Inc. Common Stock
VYNT
VYNT was delisted on the 12th of May, 2023.
26 hedge funds and large institutions have $8.36M invested in Vyant Bio, Inc. Common Stock in 2017 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 5 increasing their positions, 11 reducing their positions, and 5 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
7% less funds holding
Funds holding: 28 → 26 (-2)
34% less capital invested
Capital invested by funds: $12.6M → $8.36M (-$4.28M)
40% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 5
55% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$256K |
| 2 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
+$172K |
| 3 |
VF
Virtu Financial
New York
|
+$64.6K |
| 4 |
HF
HRT Financial
New York
|
+$53.2K |
| 5 |
TSS
Two Sigma Securities
New York
|
+$50.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EI
EAM Investors
Solana Beach,
California
|
-$422K |
| 2 |
TDC
Thompson Davis & Co
Richmond,
Virginia
|
-$224K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$104K |
| 4 |
EGA
Eagle Global Advisors
Houston,
Texas
|
-$88K |
| 5 |
PCM
Perkins Capital Management
Wayzata,
Minnesota
|
-$75.1K |
VYNT Hedge Fund Activity: Q3 2017 in Review
26 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Vyant Bio, Inc. Common Stock (VYNT) for Q3 2017, worth a combined $8.36M — down 34% from $12.6M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of VYNT and 3 opened new positions — a net loss of 2 holders — while 11 trimmed existing stakes and 5 added.
The largest buyer was UBS Group, adding an estimated $256K. The largest seller was EAM Investors, exiting entirely with an estimated $422K sold.
- 26 institutional investors held Vyant Bio, Inc. Common Stock (VYNT) as of Q3 2017, down from 28 in Q2 2017.
- Funds reported $8.36M of Vyant Bio, Inc. Common Stock stock for Q3 2017, down 34% quarter-over-quarter.
- 3 funds opened new Vyant Bio, Inc. Common Stock positions in Q3 2017 and 5 closed out, a net change of -2 holders.
- The largest Vyant Bio, Inc. Common Stock buyer in Q3 2017 was UBS Group, an estimated $256K added.
- The largest Vyant Bio, Inc. Common Stock seller in Q3 2017 was EAM Investors, an estimated $422K sold.
Based on aggregated 13F filings for Q3 2017.